(Q43793343)

English

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study

scientific article published on 11 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study (English)

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

10

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Barbara Schmalfeldt

9

object named as

Barbara Schmalfeldt

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Mariusz Bidziński

11

object named as

Mariusz Bidzinski

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Giovanni Scambia

3

object named as

Giovanni Scambia

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

author name string

Paul Sabbatini

1

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Philipp Harter

2

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Jalid Sehouli

4

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Werner Meier

5

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Pauline Wimberger

6

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Klaus H Baumann

7

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Christian Kurzeder

8

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Antonio Casado

12

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Andrea Martoni

13

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Nicoletta Colombo

14

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Robert W Holloway

15

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Luigi Selvaggi

16

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Andrew Li

17

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Jose del Campo

18

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Karel Cwiertka

19

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Tamas Pinter

20

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Jan B Vermorken

21

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Eric Pujade-Lauraine

22

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Simona Scartoni

23

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Monica Bertolotti

24

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Cecilia Simonelli

25

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Angela Capriati

26

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Carlo Alberto Maggi

27

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Jonathan S Berek

28

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Jacobus Pfisterer

29

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

language of work or name

0 references

publication date

11 March 2013

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

31

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

12

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

1554-1561

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Anti-idiotype antibody vaccine therapy for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

The CA 125 gene: an extracellular superstructure dominated by repeat sequences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

25 May 2018

CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

15 August 2018

Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

15 August 2018

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

15 August 2018

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

15 August 2018

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

15 August 2018

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795662

1 December 2018

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

1 reference

https://pubmed.ncbi.nlm.nih.gov/23478059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR

1 reference

https://pubmed.ncbi.nlm.nih.gov/23478059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23478059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23478059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological properties of a single-chain fragment of the anti-idiotypic antibody ACA125

1 reference

https://pubmed.ncbi.nlm.nih.gov/23478059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23478059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

1 reference

https://pubmed.ncbi.nlm.nih.gov/23478059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2012.46.4057

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 February 2018

http://europepmc.org/abstract/PMC/5795662

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43793343&oldid=2103381541"